Reviva Pharmaceuticals (NASDAQ:RVPH) Posts Earnings Results, Beats Estimates By $0.37 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) released its quarterly earnings results on Saturday. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.37, FiscalAI reports.

Reviva Pharmaceuticals Price Performance

Shares of RVPH opened at $0.74 on Monday. The business has a fifty day moving average of $4.27 and a 200 day moving average of $7.91. The company has a market cap of $4.78 million, a PE ratio of -0.08 and a beta of 0.10. Reviva Pharmaceuticals has a 52-week low of $0.67 and a 52-week high of $23.20.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on RVPH shares. Chardan Capital reissued a “buy” rating and set a $40.00 price target on shares of Reviva Pharmaceuticals in a research report on Monday, January 5th. D. Boral Capital lowered shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Reviva Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $66.67.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals during the second quarter valued at $31,000. Lido Advisors LLC bought a new position in shares of Reviva Pharmaceuticals during the third quarter valued at approximately $37,000. NewEdge Advisors LLC purchased a new position in shares of Reviva Pharmaceuticals in the 1st quarter valued at $58,000. State Street Corp grew its stake in Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares during the last quarter. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.